Company: BSX
Filing Date: 2025-03-19
Form Type: DEF 14A
Source: 0000885725-25-000017
Chunk: 83

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-03-19
Form: DEF 14A
Chunk 83
---
2024 |              |   680,411 |     |                   |  1,887,957 |     |                    |   549,993 |     |                                            |   770,627 |     |                                                         |  89,996 |     |                             |     48,092 |     |             |  4,027,076 |
| Executive Vice Presidentand President, PeripheralInterventions        |     |      |      |           | 2023 |              |   652,646 |     |                   |  1,759,429 |     |                    |   524,992 |     |                                            |   734,422 |     |                                                         |  60,008 |     |                             |     51,498 |     |             |  3,782,995 |
|                                                                       |     | 2022 |      |   631,986 |      |              | 1,812,175 |     |                   |    524,989 |     |                    |   482,251 |     |                                            |    75,000 |     |                                                         |  35,843 |     |                             |  3,562,244 |     |             |            |

(1) The amounts in this column for 2024 reflect an amount calculated by prorating the 2023 base salary in February when the salaries changed. These figures differ from those in the Compensation Discussion & Analysis for the applicable year, which lists amounts approved by the Compensation Committee for 2024.

(2) The amounts included in the “Stock Awards” column represent the aggregate grant date fair value of all service-based and performance-based RSUs granted in 2022, 2023 and 2024 under our 2011 LTIP, as effective on the respective dates of grant. These values have been determined in accordance with FASB ASC Topic 718.

The attainment of the performance metric for performance-based RSUs awarded to our NEOs in 2024 is based on either (i) the TSR of our common stock relative to the TSR of the common stock of the other companies in the S&P 500 Health Care Index over a three-year performance and service period or (ii) our ONSG over a three-year performance and service period, comparing actual ONSG performance against the financial plan for the period beginning on January 1, 2024 and ending on December 31, 2026 . For additional information with respect